Should radioimmunotherapy be an initial treatment option in advanced-stage follicular lymphoma?
Carol S Portlock
Correspondence Memorial Sloan–Kettering Cancer Center, Lymphoma Service, 1275 York Avenue, New York, NY 10021, USA
Email portlocc@mskcc.org
This article has no abstract so we have provided the first paragraph of the full text.
Follicular lymphomas are indolent diseases, considered incurable when advanced in stage. Radioimmunotherapy combines radiation (delivered by radiolabeling with 131I for tositumomab, Bexxar®; or with 90Y for ibritumomab tiuxetan, Zevalin®) with anti-CD20 monoclonal antibody tumor-cell targeting. Both 131I tositumomab and 90Y ibritumomab tiuxetan are FDA-approved for rituximab-refractory or relapsing follicular lymphoma. However, where to position radioimmunotherapy in the armamentarium of therapeutic options for follicular lymphoma remains a pivotal question for future study.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.